{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:18:55Z","timestamp":1776824335547,"version":"3.51.2"},"reference-count":0,"publisher":"OAE Publishing Inc.","content-domain":{"domain":["oaepublish.com"],"crossmark-restriction":false},"short-container-title":["CDR"],"DOI":"10.20517\/cdr.2021.34","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T01:47:13Z","timestamp":1623203233000},"update-policy":"https:\/\/doi.org\/10.20517\/oae.crossmark.policy","source":"Crossref","is-referenced-by-count":6,"title":["Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment"],"prefix":"10.20517","author":[{"given":"Sanam","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8410","published-online":{"date-parts":[[2021]]},"container-title":["Cancer Drug Resistance"],"original-title":[],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:45:36Z","timestamp":1705567536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oaepublish.com\/articles\/cdr.2021.34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"URL":"https:\/\/doi.org\/10.20517\/cdr.2021.34","relation":{},"subject":[],"published":{"date-parts":[[2021]]}}}